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Summary After stent implantation in the coronary arteries, patients sometimes
have to undergo invasive examination or treatments that mandate discontinuation of
antiplatelet therapy for several days. We encountered two cases of acute coronary
syndrome that occurred after preoperative discontinuation of antiplatelet agents in
the chronic phase after stent implantation. In the ﬁrst case, antiplatelet agents were
temporarily stopped 5 months after the implantation of a bare metal stent (BMS)
in preparation for a kidney transplant. In the second case, antiplatelet agents were
stopped 1.5 months after BMS implantation in preparation for esophageal bypass
surgery. In both cases, acute myocardial infarction occurred just after the invasive
operation, despite the fact that they had continued dual antiplatelet therapy for the
period recommended by the American Heart Association/American College of Cardi-
ology guideline. This report provides a warning about the temporary discontinuation
of antiplatelet agents even in the chronic stage of coronary stent implantation.
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reserved.After stent implantation in the coronary arteries,
the patients sometimes have to undergo inva-
sive examination or treatment. In such cases, the
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atients must stop taking antiplatelet agents for
everal days before the invasive procedure. There
re many reports about in-stent thromboses that
ccurred after discontinuation of antiplatelet ther-
py within a fewmonths of stent implantation [1,2].
he American Heart Association/American College
f Cardiology (AHA/ACC) guideline recommends
gy. Published by Elsevier Ireland Ltd. All rights reserved.
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Figure 1 Angiographic ﬁndings of Case 1. (A) Coronary angiography (CAG) revealed a severe stenosis in the mid-portion
of the left anterior descending artery (LAD). (B) A Liberte stent (2.75mm× 24mm) was successfully implanted in the
LAD on May 25, 2007. (C) Final angiogram of Liberte stent implantation. (D) CAG was performed on October 24, 2007.
T lloon
m ulari
t
a
m
6
t
o
t
i
f
H
t
s
c
a
t
t
a
a
l
d
o
t
t
e
t
C
C
A
t
2
t
S
u
S
r
s
r
l
w
M
2
l
uhe picture shows thrombosis in the Liberte stent. (E) Ba
ax. 10 atm). (F) Final angiogram of target lesion revasc
hat patients should be treated with clopidogrel
nd aspirin for 1 month after BMS implantation, 3
onths after sirolimus-eluting stent implantation,
months after paclitaxel-eluting stent implanta-
ion, and ideally, up to 12 months if possible, in
rder to provide continued protection for in-stent
hrombosis [3]. The U.S. Food Drug and Admin-
stration recommends adherence to the labeling
or use of stents to avoid in-stent thrombosis.
owever, it is unclear how long dual antiplatelet
herapy should be continued before the patients
afely stop antiplatelet agents. Here we report two
ases of acute coronary syndrome that occurred
fter preoperative discontinuation of antiplatelet
herapy following stent implantation. In both of
he cases reported here, the patients had been
dministered dual antiplatelet agents for at least
s long as recommended by the AHA/ACC guide-
ine, but stent thrombosis occurred during the
iscontinuation of antiplatelet therapy in the peri-
perative period. This report will alert physicians
hat preoperative discontinuation of antiplatelet
herapy may be a risk for acute coronary syndrome
ven in the chronic stage after stent implanta-
ion.
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dangioplasty was performed (Voyager, 2.75mm× 20mm,
zation.
ase reports
ase 1
51-year-old man was admitted to our hospi-
al to undergo kidney transplantation in October
007. He had a past history of diabetic nephropa-
hy, and had started to undergo hemodialysis in
eptember 2006. He was admitted to our hospital to
ndergo kidney transplantation on April 24, 2007.
tress thalium scintigraphy performed on April 27
evealed stress-induced ischemia in the antero-
eptal area of the heart. Coronary angiography
evealed severe stenosis in the mid-portion of the
eft anterior descending artery (Fig. 1A). He under-
ent percutaneous coronary intervention (PCI) on
ay 25, 2007. A bare metal stent (Liberte stent,
.75mm× 24mm) was implanted in the stenotic
esion (Fig. 1B and C). Dual antiplatelet therapy
sing 100mg of aspirin and 200mg of ticlopidine
er day was started and he was discharged from the
ospital on May 30. The patient was subsequently
eadmitted to the hospital for kidney transplanta-
ion on October 10. Aspirin and ticlopidine were
iscontinued and intravenous administration of
472 H. Fujimoto et al.
Figure 2 Angiographic ﬁndings of Case 2. (A) Coronary angiography (CAG) was performed in June 2008. There was a
severe stenosis in the mid-portion of the right coronary artery (RCA). (B) A Driver stent (3.5mm× 18mm) was implanted
in the RCA on July 2. (C) Final angiogram at percutaneous coronary intervention showed adequate dilatation of the
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ostent. (D) Acute myocardial infarction occurred on Septe
the Driver stent. (E) After thrombectomy and balloon dila
stent (3.5mm× 15mm) was successfully implanted in the
revascularization.
heparin at a dose of 400—600 units/h was started
on October 11, keeping the activated partial throm-
boplastin time (APTT) between 40 and 60 s. On
October 23, oral administration of beta-blocker
(5mg of bisoprolol per day) was stopped. On Octo-
ber 24, he underwent kidney transplantation. In the
morning of the next day, he complained of chest
compression. The time from discontinuation of hep-
arin to the onset of chest compression was 18 h.
An electrocardiogram (ECG) showed ST elevation
in leads V1—V5. He underwent emergent coronary
angiography, which showed deﬁnite thrombosis
according to the Academic Research Consortium
(ARC) deﬁnitions in the existing Liberte stent
(Fig. 1D). Red thrombus was collected by thrombec-
tomy followed by successful balloon angioplasty
(Voyager, 2.75mm× 20mm, max. 10 atm, Fig. 1E).
Peak serum creatine kinase was 1200 IU/ml (16 h
after the onset). There were no other major com-
plications and the patient was discharged from the
hospital on December 9.Case 2
A 66-year-old man was admitted to our hospital
with the diagnosis of carcinoma of the esopha-
s
t
c
dr 3. CAG showed thrombosis at the proximal portion of
n (Marverick, 3.75mm× 20mm, 12 atm), another Driver
ombosed lesion. (F) Final angiogram of the target lesion
us on June 15, 2007. Stress scintigraphy revealed
tress-induced ischemia in the inferior wall. He
nderwent coronary angiography (CAG) on June
0. CAG showed severe stenosis in the mid-
ortion of the right coronary artery (RCA). He
tarted dual antiplatelet therapy (100mg of aspirin
nd 200mg of ticlopidine per day), and under-
ent PCI on July 2. A bare metal stent (Driver
tent, 3.5mm× 18mm) was successfully implanted
Fig. 2A—C). Aspirin and ticlopidine were discon-
inued and intravenous administration of heparin
t a dose of 500—700 units/h was started on August
2, 2007, keeping APTT between 40 and 60 s. Oral
dministration of beta-blocker (60mg of meto-
rolol) was stopped on August 18. He underwent
sophageal bypass surgery on August 19, 2007. Hep-
rin was restarted on August 22. However, before
estarting the antiplatelet and beta-blocker ther-
py, on September 2, he complained of chest
ain and an ECG revealed ST elevation in leads
I, III, and aVF. He underwent emergent CAG
n suspicion of acute myocardial infarction. CAG
howed deﬁnite thrombosis in the stent according
o the ARC deﬁnitions (Fig. 2D). Red thrombus was
ollected by thrombectomy followed by balloon
ilatation and the implantation of another Driver
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RCS at the chronic phase of stent implantation
tent (3.5mm× 15mm, Fig. 2E and F). Serum cre-
tine kinase rose to 1626 IU/ml 18 h after the onset
f myocardial infarction.
iscussion
ere we report two cases of acute coronary
yndrome that occurred after preoperative discon-
inuation of antiplatelet therapy in the chronic
hase of stent implantation. There are no clear
uidelines and deﬁnitive strategy for the treatment
f patients who undergo stent implantation and
ave to discontinue antiplatelet therapy in prepa-
ation for an invasive treatment. According to the
HA/ACC recommendation, in order to prevent in-
tent thrombosis after coronary stent implantation,
atients should be treated with clopidogrel and
spirin for at least 1 month after BMS implanta-
ion [3]. These are based on the anticipated time
t takes for the stent struts to become adequately
ndothelialized. In the cases presented here, acute
oronary syndrome occurred because of discontin-
ation of dual antiplatelet therapy; in Case 1 after
months and in Case 2 after 1.5 months. Based on
hese ﬁndings, care should be exercised when dis-
ontinuing antiplatelet therapy even in the chronic
hase after stent implantation.
Thus far, several risk factors of in-stent throm-
osis have been reported, morphological and
rocedural factors such as long stents, small ves-
els, and suboptimal stent results, as well as clinical
actors such as advanced age, renal failure, dia-
etes, and the use of immunosuppressive agents
hat may promote endothelial dysfunction [4—8]. In
ase 1, several factors such as relatively small stent
2.75mm in diameter), renal failure, diabetes, and
mmunosuppressive agents might have contributed
o the in-stent thrombosis. However, in Case 2,
here seems to be no additional risk factors other
han discontinuation of antiplatelet therapy. So we
hould reconsider the period of dual antiplatelet
herapy after stent implantation, and take more
are to avoid in-stent thrombosis even if the patient
eems to have little risk for in-stent thrombosis.
Several pathological mechanisms of stent throm-
osis have been reported [9]. In the two cases
f our report, there is a possibility that plaque
upture occurred at the proximal portion of the
tents, or there had been a plaque prolapse at
tent struts, inducing stent thrombosis. It was
lso reported that thrombosis is closely related to
he hyper-inﬂammatory state [10—12]. In both of
ur cases, inﬂammatory reaction might have been
voked at the stent sites by stopping aspirin. Anti-
nﬂammatory drugs such as statins might be useful473
n such cases [13]. In any case, discontinuation of
ntiplatelet drugs might have been the most crucial
rigger for stent thrombosis.
According to another AHA/ACC advisory regard-
ng the discontinuation of dual antiplatelet therapy
n patients with coronary artery stents [14], implan-
ation of BMS or balloon angioplasty should be
onsidered in patients who are undergoing prepa-
ation for PCI and are likely to require invasive or
urgical procedures within the next 12 months. In
oth cases reported here, it might have been bet-
er to perform as a ﬁrst treatment option PCI by
alloon angioplasty only.
The AHA/ACC advisory described above also
tates that aspirin should be continued if possi-
le for patients treated with coronary stents who
re to undergo subsequent procedures that man-
ate discontinuation of thienopyridine therapy, and
hat thienopyridine should be restarted as soon as
ossible after the procedure [14]. In these two
ases, it might have been better to perform kidney
ransplantation and esophageal bypass surgery with
ontinuing aspirin if at all possible, or consider the
se of other antiplatelets that have shorter half-
ife-time such as cilostazol and beraprost, etc. until
few days before the surgical procedure.
The AHA/ACC guideline also recommends periop-
rative beta-blocker therapy for patients with risk
f coronary artery disease [15]. Beta-blocker ther-
py had been discontinued for 1 day in Case 1, and
4 days in Case 2 when stent thrombosis occurred.
iscontinuation of the beta-blocker might also have
ontributed to the in-stent thrombosis. Administra-
ion of intravenous beta-blocker may be effective
o prevent stent thrombosis when the patient can-
ot take oral therapy.
In conclusion, we encountered two cases of
cute coronary syndrome that occurred after pre-
perative discontinuation of antiplatelet therapy in
he chronic phase of stent implantation. This report
rovides a warning about the temporary discontin-
ation of antiplatelet therapy in the chronic state
f coronary stent implantation.
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